ISRCTN17701271进行中（未招募）4 期
Airway Dysfunction, Occlusions and RemodEling: COPD Patients and Mepolizumab (ADORE)
适应症
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 55 Years 至 85 Years（—）
- 性别
- All
入选标准
- •Patient understands study procedures and is willing to participate in the study as indicated by the patient’s signature
- •Provision of written, informed consent prior to any study specific procedures
- •Males and females 55–85 years of age
- •An eosinophilic phenotype with elevated BEC with a documented measurement of =300 cells/µL at Baseline/screening Visit 1
- •CT mucus-count =3 on baseline/screening CT OR on previous clinical CT acquired within last 12 weeks AND evaluable for mucus occlusions
- •Moderate to severe COPD with frequent exacerbations, defined as:
- •A clinically documented history of COPD as defined by the American Thoracic Society/European Respiratory Society for at least 1 year
- •A post-salbutamol FEV1/FVC ratio of < 0.70 and a post-salbutamol FEV1 = 30% and < 80% predicted at screening
- •A well-documented history (e.g., medical record verification) of at least 2 moderate or 1 severe exacerbation in the 12 months prior to screening:
- •At least one qualifying exacerbation must have occurred while participant is on ICS-LAMA-LABA
- •Moderate exacerbations must have been treated with systemic corticosteroids
- •Severe exacerbations are those requiring hospitalization (i.e., =24 hours)
- •Smoking status: Ex-cigarette smokers (quit = 1 year) with a history of cigarette smoking of =10 pack-years at Baseline/screening Visit 1
- •Participants should be on maintenance inhaler therapy, defined as ICS+LAMA+LABA, either as multiple inhalers or a single combination inhaler for at least 3 months prior to Baseline Visit 1
- •Participants on adjunctive COPD therapies such as roflumilast, chronic macrolide antibiotics may participate, provided they have been on these medications for at least 6 months, and on a stable dose for at least 3 months immediately prior to Baseline Visit
- •These participants should remain on these therapies for the duration of the study
- •Women of non-childbearing potential will be included
- •Such females will be:
- •Permanently sterile due to one of the following procedures:
- •a. Documented hysterectomy
- •b. Documented bilateral salpingectomy
- •c. Documented bilateral oophorectomy
- •For permanently sterile individuals due to an alternate medical cause other than the above, (e.g., Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), investigator discretion should be applied to determining study entry. If reproductive status is questionable, additional evaluation should be considered.
- •Note: Documentation will stem from review of participant’s medical records, medical examination, or medical history interview.
- •Postmenopausal female.
- •Females who are confirmed post-menopausal for =1year
- •A postmenopausal state is defined as no menses for 12 months without an alternative medical cause
- •A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in participants not using hormonal contraception or HRT. In the absence of 12 months of amenorrhea, confirmation with more than one FSH measurement is required
- •Females on HRT and whose menopausal status is in doubt must discontinue HRT to allow confirmation of postmenopausal status before study enrolment
排除标准
- •Patient has an implanted mechanically, electrically, or magnetically-activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) (at the discretion of the MRI Technologist)
- •In the Investigator’s opinion, participant suffers from any physical, psychological, or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia
- •Participant is unable to perform spirometry or plethysmography maneuvers
- •Participant is unable to perform MRI and CT breath-hold maneuvers
- •Participants with any diagnosis of asthma at any time are excluded. A diagnosis of asthma should be based on both a history of typical respiratory symptoms combined with evidence of variable expiratory airflow limitation at the time of diagnosis consistent with GINA 2023 or other accepted guidelines
- •Participants with a1-antitrypsin deficiency as the underlying cause of COPD are excluded. Also excluded are participants with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
- •Participants with pneumonia, active COPD exacerbation at screening/baseline visit, or lower respiratory tract infection within the 4 weeks prior to Baseline Visit 1
- •Participants with a history of, or plan for lung volume reduction surgery/endobronchial valve procedure
- •Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Baseline Visit 1 are excluded. Participants who are in the maintenance phase of a pulmonary rehabilitation program may participate
- •Patients requiring oxygen supplementation for more than 12 hours per day are excluded. Non-continuous (i.e., 12 hours or less per day) oxygen is permitted up to 2 L/min at screening
- •Participants with Cor-pulmonale resulting in right heart failure, severe pulmonary hypertension
- •Participants with chronic hypercapnia requiring BiPAP
- •Participants with unstable cardiovascular disease
- •Participants with other conditions that could lead to elevated eosinophils such as Hypereosinophilic syndromes including Eosinophilic Granulomatosis with Polyangiitis (EGPA, also known as Churg-Strauss Syndrome), or Eosinophilic Esophagitis
- •Participants with a known, pre-existing parasitic infection within 6 months of Baseline Visit 1
- •Participants with a current malignancy or previous history of cancer in remission for less than 12 months prior to Baseline Visit 1 (localized carcinoma of the skin or cervix resected for cure not excluded)
- •Participants with a known immunodeficiency (e.g., human immunodeficiency virus-HIV)
- •Participants with cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice. NOTE: stable non-cirrhotic liver disease (including Gilbert’s syndrome, asymptomatic gallstones, and chronic stable hepatitis B (in whom Hepatitis D (HDV) has been excluded)) or C are acceptable if participant otherwise meets entry criteria
- •Participants with (historical or) current evidence of clinically significant, neu
研究者
相似试验
招募中
不适用
Study of management in adult patients having obstruction in their main windpipeCTRI/2024/06/069195Tata memorial Centre Mumbai200
招募中
不适用
Treatment Failure of Continuous Positive Airway Pressure (CPAP) in Patients With Obstructive Sleep Apnea Syndrome (OSA): A Trial Comparing Polysomnography and the Sunrise Device to Drive Treatment-Adjustment Decisions.Sleep Apnea Syndrome, ObstructiveNCT07530302University Hospital, Grenoble105
招募中
不适用
Investigation and Classification of Treatable Traits in Patients With Chronic Airway DiseasesNCT07472738Beijing Chao Yang Hospital950
尚未招募
2 期
This is a study to Compare how well nebulization with lignocaine alone and lignocaine with dexmedetomidine works for patients going for awake nasal intubation using a fiber optic scope.CTRI/2024/06/068262Institute Department of Anaesthesiology and Critical care PGIMS ROHTAK50
Unknown
4 期
气道廓清功能改善气道黏液高分泌ChiCTR2400085237厦门市医疗卫生指导性项目